Menu Search
Equities

Sartorius AG

SRTX:GER

Sartorius AG

Actions
Health CareMedical Equipment and Services
  • Price (EUR)186.60
  • Today's Change-3.60 / -1.89%
  • Shares traded3.03k
  • 1 Year change-8.53%
  • Beta0.4792
Data delayed at least 15 minutes, as of Nov 08 2024 16:35 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Forecasts data is unavailable for this security.

Consensus recommendation

  • 16-Nov-23
  • 15-Aug-24
  • 19-Sep-24
  • 17-Oct-24
  • 07-Nov-24
Select bar for recommendation details.
Recommendations07-Nov-24
Buy0
Outperform2
Hold1
Sell0
Strong Sell0

Share price forecast in EUR

The 3 analysts offering 12 month price targets for Sartorius AG have a median target of 310.00, with a high estimate of 350.00 and a low estimate of 212.00. The median estimate represents a 66.13% increase from the last price of 186.60.
High87.6%350.00
Med66.1%310.00
Low13.6%212.00

Dividends in EUR

In 2023, Sartorius AG reported a dividend of 0.73 EUR, which represents a 48.95% decrease from last year. The 11 analysts covering the company expect dividends of 0.76 EUR for the upcoming fiscal year, an increase of 3.97%.
Div growth (TTM)-48.95%
More ▼

Earnings history & estimates in EUR

On Oct 17, 2024, Sartorius AG reported 3rd quarter 2024 earnings of 0.87 per share.
The next earnings announcement is expected on Jan 24, 2025.
Average growth rate-3.29%
Sartorius AG reported annual 2023 earnings of 4.94 per share on Feb 16, 2024.
Average growth rate+24.30%
More ▼

Revenue history & estimates in EUR

Sartorius Aktiengesellschaft had 3rd quarter 2024 revenues of 793.60m. This missed the 819.04m consensus estimate of the 2 analysts following the company. This was 12.13% below the prior year's 3rd quarter results.
Average growth rate-0.38%
Sartorius Aktiengesellschaft had revenues for the full year 2023 of 3.40bn. This was 18.66% below the prior year's results.
Average growth rate+19.47%
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.